Performance of STOK Stoke Therapeutics | 23.9% in 12m
Compare STOK with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Stoke Therapeutics with its related Sector/Index XBI
Performance Duell STOK vs XBI
| TimeFrame | STOK | XBI |
|---|---|---|
| 1 Day | -0.93% | -1.52% |
| 1 Week | 20.4% | 1.45% |
| 1 Month | 15.4% | 10.08% |
| 3 Months | 158.4% | -1.30% |
| 6 Months | 233.3% | 24.09% |
| 12 Months | 23.9% | 6.83% |
| YTD | 137.2% | 1.05% |
| Rel. Perf. 1m | 0.67 | |
| Rel. Perf. 3m | 9.10 | |
| Rel. Perf. 6m | 8.35 | |
| Rel. Perf. 12m | 1.30 |
Is Stoke Therapeutics a good stock to buy?
No, based on ValueRay Fundamental Analyses, Stoke Therapeutics (NASDAQ:STOK) is currently (May 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -74.11 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of STOK as of May 2024 is 15.50. This means that STOK is currently undervalued and has a potential upside of +11.51% (Margin of Safety).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of STOK as of May 2024 is 15.50. This means that STOK is currently undervalued and has a potential upside of +11.51% (Margin of Safety).
Is STOK a buy, sell or hold?
- Strong Buy: 6
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
Values above 0%: STOK is performing better - Values below 0%: STOK is underperforming
Compare STOK with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 18.71% | 8.42% | 215.94% | -4.42% |
| US NASDAQ 100 | QQQ | 18.39% | 6.40% | 217.27% | -11.26% |
| US Dow Jones Industrial 30 | DIA | 18.96% | 9.89% | 218.55% | 1.98% |
| German DAX 40 | DBXD | 20.59% | 10.20% | 216.17% | 9.51% |
| UK FTSE 100 | ISFU | 18.81% | 5.80% | 217.09% | 9.24% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 19.20% | 10.62% | 231.21% | 31.17% |
| Hongkong Hang Seng | HSI | 18.20% | -7.51% | 229.64% | 29.30% |
| Japan Nikkei 225 | EXX7 | 19.29% | 14.47% | 221.55% | 13.16% |
| India NIFTY 50 | INDA | 17.93% | 12.15% | 215.75% | -5.93% |
| Brasil Bovespa | EWZ | 20.44% | 12.06% | 237.09% | 11.18% |
STOK Stoke Therapeutics vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 19.16% | 11.40% | 216.15% | -11.89% |
| Consumer Discretionary | XLY | 19.88% | 10.08% | 226.54% | 5.06% |
| Consumer Staples | XLP | 19.30% | 10.29% | 219.01% | 17.86% |
| Energy | XLE | 18.88% | 15.36% | 219.37% | 0.53% |
| Financial | XLF | 18.36% | 10.12% | 211.40% | -8.77% |
| Health Care | XLV | 18.36% | 10.05% | 219.02% | 10.64% |
| Industrial | XLI | 20.21% | 11.32% | 214.00% | -3.82% |
| Materials | XLB | 19.95% | 11.76% | 217.51% | 4.29% |
| Real Estate | XLRE | 18.11% | 7.32% | 224.53% | 13.03% |
| Technology | XLK | 17.78% | 5.33% | 218.67% | -11.71% |
| Utilities | XLU | 18.85% | 4.79% | 214.77% | 10.70% |
| Aerospace & Defense | XAR | 19.28% | 6.99% | 219.08% | -0.54% |
| Biotech | XBI | 18.90% | 5.27% | 209.24% | 17.06% |
| Homebuilder | XHB | 19.77% | 8.35% | 203.07% | -26.96% |
| Retail | XRT | 20.83% | 8.66% | 213.23% | -5.61% |
Does Stoke Therapeutics outperform its market, is STOK a Sector Leader?
Yes, over the last 12 months Stoke Therapeutics (STOK) made 23.89%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.83%.
Over the last 3 months STOK made 158.36%, while XBI made -1.30%.
Yes, over the last 12 months Stoke Therapeutics (STOK) made 23.89%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.83%.
Over the last 3 months STOK made 158.36%, while XBI made -1.30%.
| Period | STOK | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 15.35% | 10.08% | 6.93% |
| 3 Months | 158.36% | -1.30% | 6.91% |
| 12 Months | 23.89% | 6.83% | 28.31% |